Key result
Low-dose aspirin shows evidence of chemopreventive effects against colorectal and other cancers.
Why the study?
The role of aspirin in primary prevention remains controversial due to contradictory guidelines and emerging evidence of its chemopreventive effects against colorectal and other cancers.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Epidemiological studies have shown aspirin to reduce the incidence of formation of polyps and thus reduce the probability of developing colon cancer. Recent studies have shown that aspirin also has an immunologic effect, which explains why low metastatic colon cancers may be seen in patients who were on aspirin.”
Review reveals chemopreventive effects of aspirin against colorectal cancer in older adults, highlighting conflicting international guidelines.
The place of aspirin in primary prevention remains controversial, with North American and European organizations issuing contradictory treatment guidelines. More recently, the U.S. Preventive Services Task Force recommended "initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years." This recommendation reflects increasing evidence for a chemopreventive effect of low-dose aspirin against colorectal (and other) cancer. The intent of this paper is to review the evidence supporting a chemopreventive effect of aspirin, discuss its potential mechanism(s) of action, and provide a conceptual framework for assessing current guidelines in the light of ongoing studies.
No takes yet. Share an insight, caveat, or question.
Paola Patrignani (2016) conducted a review in Cardiovascular disease and colorectal cancer. Aspirin was evaluated. This review discusses the evidence supporting a chemopreventive effect of low-dose aspirin against colorectal and other cancers, its mechanisms, and current guidelines.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: